Becoming a "Company that Can Continue to Provide New Value"

from the beginning

Becoming a "Company that Can Continue to Provide New Value"

presenter :

President &　Representative Director
Michihiro Tsuchiya

• Today's Topics

Medium-Term Management Plan 11-15: Results in the First Two Years

• Operating Environment in the Pharmaceutical Industry

• Medium-Term Management Plan 11-15 Success in These Two Years

• FY2015 Numerical Targets

Initiatives Targeting Sustained Growth toward 2015: Issues for the Next Three Years

• For the patients -the improvements of health and treatment satisfaction-

• Future Marketing Strategy that Reflects System Reforms

Growth strategies for Remicade and Simponi

• Remicade & Simponi:Advantages

• Remicade & Simponi:Meeting the Next Treatment Needs in RA

• Remicade & Simponi:\ 100 billion of Sales in FY2013

Growth of Gilenya/Imusera

• Gilenya:Becoming a Blockbuster in 2 years after launch

Taking on Challenges in the Diabetes Area (Tenelia, TA-7284)

• Schedule of MTPC's Diabetic Drugs in Japan

• Tenelia: Priority Issues

• TA-7284 (SGLT2 inhibitor): Distinctive Features

• TA-7284(SGLT2 inhibitor): Body Weight Reduction

• Advantage in Diabetic Area

• Ideal Diabetic Treatment brought about by Two Mechanisms of Action

• Medium- to Long-term Expansion in Diabetic Area

Strategy for Nurturing New Products / Priority Products (Lexapro, Talion, Telavic)

• Lexapro: Global Evaluation

• Lexapro: Priority Issues

• Talion: Current Status

• Talion: Priority Issues

• Telavic: Current Status

• Telavic: Priority Issues and Measures

Promising Pipeline(MT-1303, MP-214, MT-4666, MT-3995, MT-9938)

• Pipeline Status (Japan)

• Pipeline Status (Overseas)

• Nurturing of Three Disease Areas: Autoimmune disease, Diabetes and Kidney Disease, CNS disease

• Nurturing of Autoimmune Disease Area

• Nurturing of Autoimmune Disease Area

• MT-1303 for Multiple Sclerosis

• Nurturing of CNS Disease Area

• Nurturing of CNS Disease Area

• MP-214 (cariprazin) for Schizophrenia

• MT-4666 for Alzheimer's Disease

• MT-4666, Treatment for Alzheimer's disease

• Nurturing of Diabetes and Kidney Disease Area

• Nurturing of Diabetes and Kidney Disease Area

• MT-3995 for Diabetes Nephropathy

• MT-9938 for Refractory Pruritus

Other Initiatives:Operational and Structural Reforms

• Strengthening and Expanding the Vaccine Business

• Strengthening and Enhancing the Generic Business

• Bolstering of Major Base Function

• Bolstering Production Bases

Other Initiatives Contributing to KAITEKI Society by orchestrating

• Contributing to KAITEKI Society by orchestrating

Toward Achievement of FY2015 Targets

• Growth Drivers in the Future

• Toward Achievement of FY2015 Targets

New Value Creation

Cautionary Statement